 |
市場調查報告書
商品編碼
1673016
PD-1 和 PD-L1 抑制劑市場按抑制劑類型、癌症類型、通路和地區分類PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, By Cancer Type, By Distribution Channel, By Geography |
||||||
價格
簡介目錄
2025 年全球 PD-1 和 PD-L1 抑制劑市場規模估計為 622.3 億美元，預計到 2032 年將達到 2043.1 億美元，2025 年至 2032 年的複合年成長率為 18.5%。
| 報告範圍 | 報告詳細資訊 | ||
|---|---|---|---|
| 基準年 | 2024 | 2025 年市場規模 | 622.3億美元 |
| 效能資料 | 2020-2024 | 預測期 | 2025-2032 |
| 預測期：2025 年至 2032 年複合年成長率 | 18.50％ | 2032 年金額預測 | 2043.1億美元 |
數字。 PD-1 和 PD-L1 抑制劑市場佔有率（%），按地區分類，2025 年
PD-1和PD-L1抑制劑是免疫查核點抑制劑，在癌症治療中已顯示出良好的效果。查核點抑制劑可透過阻斷 PD-1 和 PD-L1 蛋白質來幫助增強人體的天然抗腫瘤反應，從而幫助腫瘤逃避免疫系統的攻擊。透過阻斷這些蛋白質，查核點抑制劑使免疫系統細胞（稱為 T 細胞）能夠更有效地識別和攻擊癌細胞。 PD-1 和 PD-L1 抑制劑近年來已被核准用於治療多種癌症，包括黑色素瘤和肺癌。由於與傳統治療方法相比臨床效果的改善，這些抑制劑的市場大幅成長，預計未來幾年將以高速成長。
市場動態
全球 PD-1 和 PD-L1 抑制劑市場的成長得益於全球癌症發病率的上升以及免疫查核點抑制劑因其良好的臨床療效而被臨床廣泛採用。此外，用於治療癌症的新型 PD-1 和 PD-L1 抑制劑的核准和上市進一步推動了市場成長。然而，這些藥物的研發和生產成本高、價格昂貴等市場限制，限制了其廣泛使用。評估查核點抑制劑與其他抗癌藥物聯合治療潛力的臨床試驗正在進行中，為市場進入者提供了長期有利可圖的機會。
研究的主要特點
- 本報告對全球 PD-1 和 PD-L1 抑制劑市場進行了詳細分析，並以 2024 年為基準年，展示了預測期（2025-2032 年）的市場規模和年複合成長率（CAGR%）。
- 它還強調了各個領域的潛在商機並說明了該市場的有吸引力的投資提案矩陣。
- 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
- 該報告涵蓋了全球 PD-1 和 PD-L1 抑制劑市場的主要企業概況，基於公司亮點、產品系列、關鍵亮點、財務業績和策略等參數。
- 本報告的見解將使負責人和公司經營團隊能夠就未來的產品發布、規模擴大、市場擴張和行銷策略做出明智的決策。
- 全球 PD-1 和 PD-L1 抑制劑市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、分銷商、新進業者和金融分析師。
- 相關人員可以透過全球 PD-1 和 PD-L1 抑制劑市場分析中使用的各種策略矩陣來促進決策。
目錄：
第1章 調查目的與前提條件
- 研究目標
- 先決條件
- 簡稱
第2章 市場展望
- 報告描述
- 市場定義和範圍
- 執行摘要
- 一致的機會圖 (COM)
第3章市場動態、法規與趨勢分析
- 市場動態
- 癌症發生率/盛行率增加
- 癌症治療費用高昂
- 增加研發活動
- 影響分析
- 監管情景
- 產品發布/核准
- PEST分析
- 波特分析
- 併購情景
4.全球PD-1 和 PD-L1 抑制劑市場 - 冠狀病毒 (COVID-19) 大流行的影響
- COVID-19 流行病學
- 供需方分析
- 經濟影響
5. 2020 年至 2032 年全球 PD-1 和 PD-L1 抑制劑市場（依抑制劑類型）
- 介紹
- PD-1 抑制劑
- PD-L1 抑制劑
6. 2020 年至 2032 年全球 PD-1 和 PD-L1 抑制劑市場（按癌症類型）
- 介紹
- 腎
- 惡性黑色素瘤
- 膀胱
- 非小細胞肺癌
- 肝
- 頭部和頸部
- 其他
7. 2020 年至 2032 年全球 PD-1 和 PD-L1 抑制劑市場按分銷管道分類
- 介紹
- 醫院藥房
- 零售藥局
- 網路藥局
8. 2020 年至 2032 年全球 PD-1 和 PD-L1 抑制劑市場（按地區分類）
- 介紹
- 北美洲
- 歐洲
- 亞太地區
- 拉丁美洲
- 中東
- 非洲
第9章 競爭格局
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
第 10 章 分析師觀點
- 興衰
- 一致的機會地圖
第 11 章 參考文獻與調查方法
- 參考
- 調查方法
簡介目錄
Product Code: CMI173
Global PD-1 and PD-L1 Inhibitor Market is estimated to be valued at USD 62.23 Bn in 2025 and is expected to reach USD 204.31 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.5% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 62.23 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 18.50% | 2032 Value Projection: | USD 204.31 Bn |
Figure. PD-1 And PD-L1 Inhibitor Market Share (%), By Region 2025
PD-1 and PD-L1 inhibitors are immune checkpoint inhibitors that have shown promising results in cancer treatment. Checkpoint inhibitors help boost the body's natural anti-tumor response by blocking proteins called PD-1 and PD-L1 that help tumors evade immune system attacks. By blocking these proteins, checkpoint inhibitors allow the immune system cells called T cells to recognize and attack cancer cells more effectively. Several PD-1 and PD-L1 inhibitors have been approved in recent years for use against various cancers like melanoma, lung cancer and more. With their improved clinical outcomes compared to conventional therapies, the market for these inhibitors has grown substantially and is expected to witness high growth in the coming years.
Market Dynamics:
The global PD-1 and PD-L1 inhibitor market growth is driven by the rising prevalence of cancer worldwide and the increasing adoption of immune checkpoint inhibitors in clinical practice due to their promising clinical efficacy. Moreover, the approval and launch of new PD-1 and PD-L1 inhibitors for additional cancer indications is further fueling the market growth. However, the market faces restraints from the high costs associated with developing and manufacturing these drugs as well as their expensive pricing which limits widespread adoption. Ongoing clinical trials evaluating the potential of combining checkpoint inhibitors with other anticancer therapies presents lucrative opportunities for market players in the long run.
Key Features of the Study:
- This report provides an in-depth analysis of the global PD-1 and PD-L1 inhibitor market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global PD-1 and PD-L1 inhibitor market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Pfizer Inc., Novartis AG, AstraZeneca PLC, Gilead Sciences Inc., Amgen Inc., Sanofi AG, F. Hoffmann-La Roche AG, Merck & Co., Bristol-Myers Squibb Company, Regeneron Pharmaceuticals Inc., Merck & Co., GSK plc, Ono Pharmaceutical Co., Ltd., Eli Lilly and Company, and BeiGene LTD.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global PD-1 and PD-L1 inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PD-1 and PD-L1 inhibitor market.
Market Segmentation
- Type of Inhibitor:
- PD-1 Inhibitors
- PD-L1 Inhibitors
- Cancer Type:
- Kidney
- Melanoma
- Bladder
- Non-small Cell Lung Cancer
- Liver
- Head & neck
- Others
- Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Pfizer Inc.
- Novartis AG
- AstraZeneca PLC
- Gilead Sciences Inc.
- Amgen Inc.
- Sanofi AG
- Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- Merck & Co.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
Table of Contents:
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type of Inhibitor
- Market Snapshot, By Cancer Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Rise in incidence/prevalence of cancer
- High cost of cancer treatment
- Rise in research and development activities
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global PD-1 and PD-L1 Inhibitor Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global PD-1 and PD-L1 Inhibitor Market, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- PD-1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- PD-L1 Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global PD-1 and PD-L1 Inhibitor Market, By Cancer Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Kidney
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Bladder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Non-small Cell Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Liver
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Head & Neck
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
7. Global PD-1 and PD-L1 Inhibitor Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
8. Global PD-1 and PD-L1 Inhibitor Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type of Inhibitor, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Gilead Sciences Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi AG
- F. Hoffmann-La Roche AG
- Merck & Co.
- Bristol-Myers Squibb Company
- Regeneron Pharmaceuticals Inc.
- GSK plc
- Ono Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- BeiGene LTD
10. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
